338 related articles for article (PubMed ID: 32651333)
1. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
[TBL] [Abstract][Full Text] [Related]
3. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Williams DR; Evans AH; Fung VSC; Hayes M; Iansek R; Kimber T; O'Sullivan JD; Sue CM
Intern Med J; 2017 Oct; 47(10):1107-1113. PubMed ID: 28195385
[TBL] [Abstract][Full Text] [Related]
4. [Device-aided therapies in advanced Parkinson's disease].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):54-60. PubMed ID: 28139627
[TBL] [Abstract][Full Text] [Related]
5. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
6. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
[TBL] [Abstract][Full Text] [Related]
7. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Mundt-Petersen U; Odin P
Int Rev Neurobiol; 2017; 134():1019-1044. PubMed ID: 28805563
[TBL] [Abstract][Full Text] [Related]
8. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
9. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
[TBL] [Abstract][Full Text] [Related]
10. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Elia AE; Dollenz C; Soliveri P; Albanese A
Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
Ludin HP; Surber Ch
Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
[TBL] [Abstract][Full Text] [Related]
12. [Levodopa intestinal infusion therapy in Parkinson's disease].
Sławek J; Bogucki A
Neurol Neurochir Pol; 2010; 44(4):396-403. PubMed ID: 20827613
[TBL] [Abstract][Full Text] [Related]
13. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Volkmann J; Albanese A; Antonini A; Chaudhuri KR; Clarke CE; de Bie RM; Deuschl G; Eggert K; Houeto JL; Kulisevsky J; Nyholm D; Odin P; Østergaard K; Poewe W; Pollak P; Rabey JM; Rascol O; Ruzicka E; Samuel M; Speelman H; Sydow O; Valldeoriola F; van der Linden C; Oertel W
J Neurol; 2013 Nov; 260(11):2701-14. PubMed ID: 23287972
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.
Fabbri M; Rosa MM; Ferreira JJ
Drugs Aging; 2018 Dec; 35(12):1041-1054. PubMed ID: 30318555
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine in the treatment of Parkinson's disease: a review.
Pessoa RR; Moro A; Munhoz RP; Teive HAG; Lees AJ
Arq Neuropsiquiatr; 2018 Dec; 76(12):840-848. PubMed ID: 30698208
[TBL] [Abstract][Full Text] [Related]
16. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
Wenzel K; Homann CN; Fabbrini G; Colosimo C
Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
[TBL] [Abstract][Full Text] [Related]
17. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
Antonini A; Nitu B
J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
[TBL] [Abstract][Full Text] [Related]
19. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
20. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
